GILD

Gilead Sciences (GILD) is the lead sponsor of 62 active clinical trials listed on ClinicalTrials.gov^[5], including 26 Phase 3^[1], 26 Phase 2^[2], 16 Phase 1^[3], 1 Phase 4^[4].

Trial NCT01651403^[6] evaluates Tenofovir DF in Chronic Hepatitis B with a target enrollment of 90 participants. Trial NCT05502237^[7] evaluates Zimberelimab in Non-small Cell Lung Cancer with a target enrollment of 1021 participants. Trial NCT06801834^[8] evaluates Sacituzumab Govitecan (SG) in Extensive Stage Small Cell Lung Cancer (ES-SCLC) with a target enrollment of 695 participants.

GILD has 9 Form 4 insider filings recorded at the SEC in the past 30 days^[9].